Abstract
Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited by the lack of suitable bone-marrow donors, the risk of graft-versus-host disease (GVHD) and slow immune reconstitution. Umbilical-cord blood is an alternative source of haematopoietic stem cells that has recently been tested in both child and adult cancer patients. These studies have identified several advantages to umbilical-cord cell transplantation, including a lower incidence of GVHD. Umbilical-cord blood is therefore a promising alternative to bone-marrow-derived stem cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 526-532 |
| Number of pages | 7 |
| Journal | Nature Reviews Cancer |
| Volume | 3 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2003 |
Bibliographical note
Funding Information:Supported by grants from the National Institutes of Health and the Children’s Cancer Research Fund.
